知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.034 秒)

    IMMUNOTHERAPEUTIC METHOD
    2.
    发明申请
    IMMUNOTHERAPEUTIC METHOD 失效
    免疫学方法

    公开(公告)号：US20100124534A1

    公开(公告)日：2010-05-20

    申请号：US12503512

    申请日：2009-07-15

    申请人： Richard Harrop ,  William Shingler ,  Stuart Naylor ,  Michael McDonald

    发明人： Richard Harrop ,  William Shingler ,  Stuart Naylor ,  Michael McDonald

    IPC分类号： A61K49/00 ,  A61P37/04

    CPC分类号： G01N33/6854 ,  A61K39/0011 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  C12N2799/023 ,  G01N33/574 ,  G01N33/57419 ,  G01N33/57438 ,  G01N2800/52

    摘要： The present invention provides a method of monitoring the efficacy of an immunotherapy in a mammalian subject, wherein the subject has been administered an immunotherapy, wherein the immunotherapy comprises a viral vector containing a polynucleotide encoding an antigen, wherein the viral vector is capable of transducing cells in the mammalian subject to cause the cells to express the antigen; the method comprising: (b) measuring, from a biological sample isolated from the subject, an immune response of the subject to the antigen and comparing the immune response of the subject to the antigen to a reference measurement of immune response to the antigen; (c) measuring, from a biological sample isolated from the subject, an immune response of the subject to the viral vector and comparing the immune response of the subject to the viral vector to a reference measurement of immune response to the viral vector; and (d) determining efficacy based on the comparisons of (b) and (c), wherein an elevated immune response to the antigen and a reduced immune response to the viral vector are indicative of an effective immunotherapy.

    摘要翻译： 本发明提供了监测哺乳动物受试者的免疫治疗功效的方法，其中所述受试者已经进行免疫治疗，其中所述免疫疗法包含含有编码抗原的多核苷酸的病毒载体，其中所述病毒载体能够转导细胞 在哺乳动物受试者中使细胞表达抗原; 该方法包括：（b）从分离自受试者的生物样品中测量受试者对抗原的免疫应答并将受试者与抗原的免疫应答与抗原的免疫应答的参考测量进行比较; （c）从分离自受试者的生物样品中测量受试者对病毒载体的免疫应答，并将受试者与病毒载体的免疫应答与对病毒载体的免疫应答的参考测量进行比较; 和（d）基于（b）和（c）的比较确定功效，其中对抗原的免疫应答升高和对病毒载体的免疫应答降低是指示有效的免疫治疗。

    Peptide
    4.
    发明授权
    Peptide 失效
    肽

    公开(公告)号：US08147838B2

    公开(公告)日：2012-04-03

    申请号：US11914084

    申请日：2006-05-12

    申请人： Richard Harrop ,  William Shingler ,  Susan Mary Kingsman

    发明人： Richard Harrop ,  William Shingler ,  Susan Mary Kingsman

    IPC分类号： C07K7/06

    CPC分类号： C07K14/4748 ,  C07K16/2833

    摘要： The present invention relates to peptide epitopes of 5T4 antigen and their use in immunotherapy. In particular, the present invention relates to any one of the peptide epitopes as described herein as well as their used in diagnosis and therapy of cancer.

    摘要翻译： 本发明涉及5T4抗原的肽表位及其在免疫治疗中的用途。 特别地，本发明涉及本文所述的任何一种肽表位以及它们用于癌症的诊断和治疗。

    MHC class II epitopes of 5T4 antigen
    5.
    发明授权
    MHC class II epitopes of 5T4 antigen 失效
    5T4抗原的MHC II类表位

    公开(公告)号：US07910109B2

    公开(公告)日：2011-03-22

    申请号：US10504603

    申请日：2003-02-13

    申请人： Miles Carroll ,  Susan Kingsman ,  Richard Harrop

    发明人： Miles Carroll ,  Susan Kingsman ,  Richard Harrop

    IPC分类号： A61K38/00 ,  A61K39/00 ,  A61K39/39 ,  A61K39/385 ,  C07H21/04

    CPC分类号： C07K7/08 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/5158 ,  C07K14/4748 ,  C12N2799/021

    摘要： There is provided an MHC class II peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the minimal epitope from the amino acid sequence shown as SEQ ID No. 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3; (iii) a minimal epitope from the region 281-420 of 5T4. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.

    摘要翻译： 提供了来自5T4抗原的MHC II类肽表位。 特别地，提供了5T4的肽表位，其包含以下之一：（i）如SEQ ID No.2所示的氨基酸序列的最小表位; （ii）如SEQ ID No.3所示的氨基酸序列的最小表位; （iii）来自5T4区域281-420的最小表位。 还提供了包含这种肽（或其前体）的疫苗及其用于治疗和/或预防疾病，特别是癌性疾病的用途。

    FACTORS
    10.
    发明申请
    FACTORS 审中-公开
    因素

    公开(公告)号：US20120039943A1

    公开(公告)日：2012-02-16

    申请号：US13143512

    申请日：2010-01-08

    申请人： Richard Harrop

    发明人： Richard Harrop

    IPC分类号： A61K39/00 ,  A61P35/00 ,  A61P37/04 ,  C12Q1/02

    CPC分类号： G01N33/5094 ,  G01N33/574 ,  G01N2800/52

    摘要： A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of platelets and haemoglobin in a sample from the cancer patient, and (b) comparing the level of platelets in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of platelets and higher level of haemoglobin in the sample correlates with increased benefit to the patient.

    摘要翻译： 用于确定接受免疫治疗治疗的癌症患者的益处的方法，所述方法包括：（a）测量来自癌症患者的样品中的血小板和血红蛋白的水平，和（b）将样品中的血小板水平与参考水平 的血小板，并将样品中的血红蛋白水平与血红蛋白的参考水平进行比较，其中样品中较低水平的血小板和较高水平的血红蛋白与对患者的益处增加相关。